Zai Lab A Short Ahead Of Lockup Expiration

March 19, 2018 concludes the 180-day lockup period on Zai Lab Ltd. (ZLAB).

When the lockup period ends for Zai Lab, its pre-IPO shareholders and insiders will be able to sell large blocks of previously-restricted stock for the first time. This group of shareholders includes eight individuals and five corporate entities.

(Source: F-1/A)

A likely increase of shares traded on the secondary market could negatively impact the stock price of Zai Lab in the short term. Just 16.31% of shares are currently publicly trading.

(Source: F-1/A)

Currently ZLAB trades in the $21 to $22 range. The company has a return from IPO of 20.2%.

Business Overview: Biopharmaceutical Working Developing Proprietary Therapeutics

Zai Lab Ltd. is a biopharmaceutical company with a focus on developing, licensing, and marketing proprietary therapies for cancer, infectious diseases and autoimmune disorders. (Source: F-1/A) ZLAB’s drug candidates include ZL-2306, which is a poly ADP ribose polymerase 1/2 inhibitor for treating lung, breast, and ovarian cancers; ZL-1101, an anti-OX40 antagonistic antibody to treat systemic lupus erythematosus or graft-versus-host disease; ZL-2302 for treating non-small cell lung cancer; ZL-3101, a steroid-sparing topical product in Phase II clinical trials for treating psoriasis and eczema; ZL-2301 which is currently in Phase II clinical trials for treating hepatocellular carcinoma; and ZL-2401, an antibiotic for treating acute bacterial skin infections, UTIs, and community-acquired bacterial pneumonias. (Source: F-1/A)

(Source: F-1/A)

Zai Lab was founded in 2014. In the Source: F-1/A, the company notes that is has “assembled a management team with global experience and an extensive track record in navigating the regulatory process to develop and commercialize innovative drugs in China.” (Source: F-1/A) ZLAB’s long term objectives include the development of an integrated drug discovery and development platform in order to provide in-licensed and internally-discovered medicines within China and globally. Zai Lab is currently constructing its own large molecule facility, which is expected to be completed in the first half of 2018 (See Chart Below).